Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry

Abstract excerpt

<title>Abstract</title> <p> Real-world comparisons of venetoclax (VEN)-based versus hypomethylating agent (HMA) monotherapy in unfit, newly diagnosed AML remain limited by short follow-up, low genomic testing, and inadequate statistical power. We conducted the largest comparative analysis to date from the PETHEMA registry, including 2,610 patients (929 VEN-based, 1,681 HMA). Composite complete remission was high...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Aged
• Antineoplastic Combined Chemotherapy Protocols
• Bridged Bicyclo Compounds, Heterocyclic
• Disease-Free Survival
• Genotype
• Leukemia, Myeloid, Acute
• Sulfonamides

Identifiers and source

Literature Corpus work

90bb7d1b-b531-5510-a060-a256ade3ae70

DOI

10.21203/rs.3.rs-9919354/v1